- American City Business Journals•4 days ago
After announcing disappointing Phase 2 bladder cancer treatment results in November , Durham’s Heat Biologics presented data from its trial at the Genitourinary Cancers Symposium in Orlando last week, along with company outlook in the space. “As previously reported, vaccine arms did not show a statistical improvement over the placebo arm in the primary endpoint (1-year recurrence free survival). In an interview in December, CEO Jeff Wolf said that the two-year endpoint will allow the company “to get a better look at the data as it matures …” He added that the company will then determine whether to progress its treatment HS-410 to Phase 3 trials.
- GlobeNewswire•8 days agoHeat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium
DURHAM, N.C., Feb. 17, 2017-- Heat Biologics, Inc., announced that it presented a poster of its immunological data from its 94- patient Phase 2 trial evaluating vesigenurtacel-L either alone or in combination ...
- GlobeNewswire•11 days ago
DURHAM, N.C., Feb. 14, 2017-- Heat Biologics, Inc., a leader in the development of immunotherapies designed to activate a patient’ s immune system against cancer, announced that it will present a poster ...
HTBX : Summary for Heat Biologics, Inc. - Yahoo Finance
Heat Biologics, Inc. (HTBX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.65 x 3000|
|Ask||0.85 x 500|
|Day's Range||0.71 - 0.84|
|52 Week Range||0.40 - 3.35|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.70|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|